Topic summary
BOL-148
BOL-148, also known as 2-bromo-LSD or as bromolysergide, is a non-hallucinogenicserotonin receptor modulator of the lysergamide family related to the psychedelic druglysergic acid diethylamide (LSD). It is specifically the 2-bromoderivative of LSD.
The drug is a non- or minimally-hallucinogenic serotonin5-HT2A receptorpartial agonist, as well as acting at other targets such as other serotonin receptors and dopamine receptors. The lack of psychedelic effects with BOL-148 is thought to be due to lower-efficacy partial agonism at the serotonin 5-HT2A receptor compared to LSD that is insufficient to produce hallucinogenic effects. The drug has been found to produce psychoplastogenic and antidepressant-like effects in animals.
BOL-148 was initially developed by Albert Hofmann in the 1950s, as part of the original research from which LSD was also derived. It is now being reinvestigated and is under development for the potential treatment of cluster headaches and other conditions. This is under new developmental code names including BETR-001, TD-0148A, and NYPRG-101.